Identification of Plasma Growth Factors and Cytokines as Diagnostic Biomarkers for Lafora Disease
Authors:
- Mireia Moreno-EstellésMMMireia Moreno-Estellés
- María MachioMMMaría Machio
- Laura GonzálezLGLaura González
- Marta AlbuixechMAMarta Albuixech
- Laura AbrairaLALaura Abraira
- Manuel QuintanaMQManuel Quintana
- Manuel ToledoMTManuel Toledo
- Marina P. SánchezMSMarina P. Sánchez
- Jose M. SerrratosaJSJose M. Serrratosa
- Pascual SanzPSPascual Sanz
Preprint
Abstract
Lafora progressive myoclonus epilepsy (LD, OMIM#254780, ORPHA:501) is an ultra-rare and severe autosomal recessive neurological disorder that typically manifests in early adolescence. It is characterized by the accumulation of insoluble forms of aberrant glycogen in the brain and peripheral tissues. Given the urgent need for reliable tools for diagnosis and to monitor disease progression, in this work, we aimed to identify reliable biomarkers in minimally invasive fluids, which could also provide valuable insights into the natural history of the disease. Plasma-EDTA samples from eleven LD patients and healthy controls were analyzed to identify potential biomarkers of LD. Eleven cytokines and growth factors were identified to be significantly reduced in LD patient samples compared to healthy controls. Among these, four mediators [platelet-derived growth factor subunit B (PDGF-BB), epidermal growth factor (EGF), brain derived growth factor (BDNF), and macrophage migration inhibitory factor (MIF)], exhibited the greatest fold change between the groups and were further validated. Receiver operating characteristic (ROC) analysis confirmed the robust diagnostic potential of these four proteins. Notably, the levels of these proteins were reduced even in asymptomatic patients, suggesting potential utility for early diagnosis. Given the minimally invasive nature of plasma sampling and the straightforward quantification via ELISA assays, these biomarkers hold strong promise for rapid translation to the clinic, potentially enhancing early diagnosis in LD patients. Our findings offer a promising step toward the development of accessible, non-invasive diagnostic tools for LD.,. Key points: - Several plasma biomarkers associated with Lafora disease (LD) have been identified. - These biomarkers are reduced in LD patients compared to healthy controls. - Reduced levels of these biomarkers were detectable even in asymptomatic patients. - Their reduced levels may contribute to the neurological alterations observed in LD.Keywords
This publication has 34 references indexed in Scilit:
- PDGF‐BB‐Dependent Neurogenesis Buffers Depressive‐Like Behaviors by Inhibition of GABAergic Projection from Medial Septum to Dentate GyrusAdvanced Science, 2023
- Molecular profile and peripheral markers of neurodegeneration in patients with Niemann-Pick type C: Decrease in Plasminogen Activator Inhibitor type 1 and Platelet-Derived Growth Factor type AAArchives of Biochemistry and Biophysics, 2023
- Epidermal Growth Factor in the CNS: A Beguiling Journey from Integrated Cell Biology to Multiple Sclerosis. An Extensive Translational OverviewCellular and Molecular Neurobiology, 2020
- Functional roles of GDF15 in modulating microenvironment to promote carcinogenesisBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2020
- FDG-PET assessment and metabolic patterns in Lafora diseaseEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- Targeting Pathogenic Lafora Bodies in Lafora Disease Using an Antibody-Enzyme FusionCell Metabolism, 2019
- Growth Factors and Neuroglobin in Astrocyte Protection Against Neurodegeneration and Oxidative StressMolecular Neurobiology, 2018
- Topographic Reorganization of Cerebrovascular Mural Cells under Seizure ConditionsCell Reports, 2018
- Increased Oxidative Stress and Impaired Antioxidant Response in Lafora DiseaseMolecular Neurobiology, 2014
- Beitrag zur Histopathologie der myoklonischen EpilepsieZeitschrift für die gesamte Neurologie und Psychiatrie, 1911